ALG-055009 for Fatty Liver Disease (HERALD Trial)

Palo Alto (17 mi)

Overseen byStephen Harrison, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Verified Trial

Waitlist Available

Sponsor: Aligos Therapeutics

Prior Safety Data

Trial Summary

What is the purpose of this trial?This is a Phase 2a study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of oral (PO) daily (QD) doses of ALG-055009 (soft gelatin \[softgel\] capsule) for 12 weeks.

Eligibility Criteria

This trial is for adults without liver scarring who have a condition called MASH, which is related to fat buildup in the liver. Participants should not have other serious health issues that could interfere with the study.

Inclusion Criteria

You have been diagnosed with Nonalcoholic Steatohepatitis

Treatment Details

The trial is testing ALG-055009, a new medication taken orally once daily for 12 weeks. It's being compared to a placebo (a pill with no active drug) to see if it's safe and effective for treating fatty liver diseases.

5Treatment groups

Experimental Treatment

Placebo Group

Group I: ALG-055009 softgel capsule 0.9mgExperimental Treatment1 Intervention

ALG-055009 softgel capsule 0.9mg Daily for 12 weeks

Group II: ALG-055009 softgel capsule 0.7mgExperimental Treatment1 Intervention

ALG-055009 softgel capsule 0.7mg Daily for 12 weeks

Group III: ALG-055009 softgel capsule 0.5mgExperimental Treatment1 Intervention

ALG-055009 softgel capsule 0.5mg Daily for 12 weeks

Group IV: ALG-055009 softgel capsule 0.3mgExperimental Treatment1 Intervention

ALG-055009 softgel capsule 0.3mg Daily for 12 weeks

Group V: PlaceboPlacebo Group1 Intervention